Treatment
toxicity, death
DISEASE PROGRESSION
Dose escalation proceeded using a 3 + 3 design. Patients received oleclumab 5, 10, 20, or 40 mg/kg via intravenous infusion every 2 weeks (Q2W), either as monotherapy or in combination with durvalumab 10 mg/kg intravenously Q2W (≥ 15 min after end of oleclumab infusion), until disease progression, unacceptable toxicity, death, or patient withdrawal. Dose escalation in the combination therapy cohort commenced following completion of the DLT evaluation period at the third dose level in the monotherapy cohort (Supplementary Methods for DLT definition). In the expansion phase, patients received combination therapy on the same schedule and at oleclumab 40 mg/kg.